Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network
Cancers · 28.12.2025 · 18 (1) · 97
DOI: 10.3390/cancers18010097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 28.12.2025. Verfasst von Christoph Blazejak und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Helios Klinikum Krefeld, Health and Medical University Düsseldorf-Krefeld, 47805 Krefeld, Germany. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS) are aggressive forms of cutaneous T-cell lymphoma (CTCL) for which treatment options are limited and prognosis is poor. Brentuximab vedotin (BV), an anti-CD30 antibody–drug conjugate, has demonstrated high response rates in patients with CD30 expression ≥ 10%. However, data on its efficacy in cases with low CD30 expression (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Helios Klinikum Krefeld, Health and Medical University Düsseldorf-Krefeld, 47805 Krefeld, Germany.
- Department of Dermatology, Universitätsklinikum Bochum, 44801 Bochum, Germany.
- Dermatology Practice Dr. R. Stranzenbach, 58285 Gevelsberg, Germany.
- Department of Dermatology, Vivantes Klinikum Neukölln, 12351 Berlin, Germany.
- MVZ Dermatopathologie Duisburg Essen GmbH, 45147 Essen, Germany.
- Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, 37075 Göttingen, Germany.
ORCID-Profile: Marion Wobser, Nina Booken, Alexander Kreuter, Rudolf Stadler, Chalid Assaf
Zitieren
APA
Blazejak, C., Oymanns, M., Stranzenbach, R., Hillen, U., Mitteldorf, C., Nicolay, J. P., Wobser, M., Schrüfer, P., Gosmann, J., Wehkamp, U., Booken, N., Kreuter, A., Dippel, E., Klemke, C. D., Weyermann, M., Stadler, R., & Assaf, C. (2025). Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network. Cancers, 18(1), 97. https://doi.org/10.3390/cancers18010097
Vancouver
Blazejak C, Oymanns M, Stranzenbach R, Hillen U, Mitteldorf C, Nicolay JP, et al. Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network. Cancers. 2025;18(1):97. doi:10.3390/cancers18010097
BibTeX
@article{Blazejak2025,
author = {Blazejak, Christoph and Oymanns, Mathias and Stranzenbach, René and Hillen, Uwe and Mitteldorf, Christina and Nicolay, Jan P and Wobser, Marion and Schrüfer, Philipp and Gosmann, Janika and Wehkamp, Ulrike and Booken, Nina and Kreuter, Alexander and Dippel, Edgar and Klemke, Claus-Detlev and Weyermann, Maria and Stadler, Rudolf and Assaf, Chalid},
title = {Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network},
journal = {Cancers},
year = {2025},
volume = {18},
number = {1},
pages = {97},
doi = {10.3390/cancers18010097}
}
EUVIMED